JUPITER, Fla. and BENGALURU, India — March 4, 2026 — Leads & Copy — Dyadic Applied BioSolutions and Fermbox Bio have commercially launched animal-origin-free Recombinant DNase I (RNase-free), marking the first product from their expanded collaboration announced in 2025.
Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Fermbox Bio (“Fermbox”), a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tools.
The launch signifies Dyadic’s move from platform development to commercial product expansion and recurring revenue growth.
Recombinant DNase I (RNase-free), produced using Dyadic’s high-yield fungal microbial expression platforms and Fermbox Bio’s biomanufacturing capabilities, is currently available in research grade. A cGMP-grade version is in development for biopharmaceutical manufacturing and cell and gene therapy applications.
Joe Hazelton, President & COO of Dyadic Applied BioSolutions, stated that the launch translates their expanded collaboration with Fermbox Bio into commercial products, demonstrating their ability to bring high-quality, scalable recombinant enzymes and proteins to customers.
Recombinant DNase I (RNase-free) is an endonuclease enzyme used for nucleic-acid clean-up and sample preparation workflows where residual DNA can interfere with analytical results. Its RNase-free specification supports RNA integrity in sensitive RNA workflows across biological research, biotechnology, and molecular diagnostics.
DNase I (RNase-free) is the first in a planned series of recombinant enzymes and proteins expected to be commercially introduced throughout 2026.
Planned pipeline products include recombinant α-lactalbumin, recombinant transferrin, recombinant human FGF-2, recombinant human lactoferrin, and additional recombinant proteins expressed using Dyadic’s fungal microbial platforms. The initial portfolio targets high-demand segments in cell culture media, media supplementation, and molecular biology reagents, supporting applications such as cell and gene therapy (CGT), vaccine and monoclonal antibody manufacturing, regenerative medicine, and advanced biologics development.
Under the collaboration, Dyadic provides its fungal microbial expression platforms, production strains, and development support, while Fermbox Bio leads downstream process development, scale-up, and manufacturing. The companies are aligned on global commercialization to serve research and biomanufacturing customers worldwide.
Dyadic Applied BioSolutions is a biotechnology company using its microbial platforms to produce recombinant proteins for the life sciences, food and nutrition, and bio-industrial markets. Fermbox Bio, based in India with a U.S. subsidiary, develops sustainable bio-based products using precision fermentation and advanced biotechnology.
Source: Dyadic Applied BioSolutions
